Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with antidiabetic actions in db/db mice

Endocrinology

Volumn 137, Issue 10, 1996, Pages 4189-4195

  Berger, Joel ^a   Bailey, Philip ^a   Biswas, Chhabi ^b   Cullinan, Catherine A ^b   Doebber, Thomas W ^b   Hayes, Nancy S ^b   Saperstein, Richard ^a   Smith, Roy G ^b   Leibowitz, Mark D ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Research Laboratories ^*

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; ENHANCER REGION; GENETIC REGULATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; PROTEIN CONFORMATION; REPORTER GENE; TRANSACTIVATION;

EID: 0029745382     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.137.10.8828476     Document Type: Article

References (45)

1. Lebovitz HE 1993 Insulin mimetic and insulin-sensitizing drugs. Diabetes Res Clin Pract 20:89-91
2. Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR 1983 Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 32:830-838
3. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuki Z 1983 Reduction of insulin resistance in obese and/or diabetic animal by 5[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63, 287, ciglitazone), a new antidiabetic agent. Diabetes 32:804-810
4. Sugiyama Y, Shimura Y, Ikeda H 1990 Effect of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim Forsch Drug Res 40:436-440
5. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisomal proliferator-activated receptor gamma. J Biol Chem 270: 12953-12956
6. Keller H, Wahli W 1993 Peroxisome proliferator-activated receptors. Trends Endocrinol Metab 4:291-296
7. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM 1992 Convergence of 9-cis retinoic acid and peroxisome prolifierator signaling pathways through heterodimer formation of their receptors. Nature 358:771-774
8. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W 1996 Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and γ in the adult rat. Endocrinology 137:354-366
9. Issemann I, Prince RA, Tugwood JD, Green S 1993 The peroxisome proliferator activated receptor: retinoid X receptor heterodimer is activated by fatty acid and fibrate hypolipidaemic drugs. J Mol Endocrinol 11:37-47
10. Osumi T, Wen JK, Hashimoto T 1991 Two cis-acting regulatory elements in the peroxisome proliferator-responsive element enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun 175:866-871
11. Tugwood JD, Isseman I, Anderson RG, Bundell KR, McPheat WL, Green S 1992 The mouse peroxisome-proliferator-activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11:433-439
12. Gottlicher M, Widmark E, Li Q, Gustafsson JA 1992 Fatty acids activate the clofibric acid activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89:4653-4657
13. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W 1993 Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptors-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 90:2160-2164
14. Staels B, Vu-Dac N, Kosykh V, Saladin R, Fruchart JC, Dallongeville J, Auwerx J 1995 Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl co-enzyme A oxidase. J Clin Invest 95:705-712
15. Hertz R, Bishara-Shieben J, Bar-Tana J 1995 Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III. J Biol Chem 270:13470-13475
16. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA 1992 Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acid. Mol Endocrinol 6:1634-1641
17. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM 1994 Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91:7355-7359
18. Ez-Zoubir A, Bonino F, Ailhaud G, Abumrad NA, Grimaldi PA 1995 Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. J Biol Chem 270:2367-2371
19. Tontonoz P, Erding H, Graves RA, Budavari AI, Spiegelman BM 1994 mP-PARgamma2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234
20. Zhu Y, Alvares K, Huang Q, Sambasiva Rao M, Reddy JK 1993 Cloning of a new member ot the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem 268:26817-26820
21. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD 1995 Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hemapoietic cells and chromosomal mapping. Gene Expr 4:281-299
22. 21a. Elbrechl A, Chen Y, Cullinan CA, Hayes N, Leibowitz MD, Moller DE, Berger J 1996 Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun 224:431-437
23. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Sambasiva Rao M, Reddy JK 1995 Structural organization of mouse peroxisome proliferator-activated receptor γ(mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc Natl Acad Sci USA 92:7921-7925
24. Tontonoz P, Hu E, Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid activated transcription factor. Cell 79:1147-1156
25. Hiragun A, Sato M, Mitsui H 1988 Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent. J Cell Physiol 134:124-130
26. Kletzien RF, Clarke SD, Ulrich RG 1992 Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41:393-398
27. Sandouk T, Reda D, Hofmann C 1993 Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-L1 cells. Am J Physiol 264:C1600-C1608
28. Szalkowski D, White-Carrington S, Berger J, Zhang B 1995 Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 136:1474-1481
29. Berger J, Biswas C, Hayes N, Ventre J, Wu M, Doebber TW 1996 An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissue. Endocrinology, 137:1984-1990
30. Allan GF, Xiaohua L, Tsai SY, Weigel NL, Edwards DP, Tsai M-J, O'Malley BW 1992 Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267:19513-19520
31. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
32. Aperlo C, Pognonec P, Saladin R, Auwerx J, Boulukos KE 1995 cDNA cloning and characterization of the transcriptional activities of the hamster peroxisomal proliferator-activated receptor haPPARγ. Gene 162:297-302
33. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ 1989 Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA 86:327-331
34. Hollons T, Yoshimura FK 1989 Variation in enzymatic transient gene expression assays. Anal Biochem 182:411-418
35. Hu E, Tontonoz P, Spiegelman BM 1995 Transdifferentiation of myoblasts by the adipogenic transcription factor PPARγ and C/EBPα. Proc Natl Acad Sci USA 92:9856-9860
36. Tontonoz P, Hu E, Devine J, Geale EG, Spiegelman BM 1995 PPARγ2 regulates adipose expression of the phospoenolpyruvate carboxykinase gene. Mol Cell Biol 15:351-357
37. Sizer K, Smith CL, Jacob CS, Swanson ML, Bleasdale JE 1994 Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism. Mol Cell Endocrinol 102:119-129
38. Bennett PH 1990 Epidemology of diabetes mellitus. In: Rifkin H, Porte D (eds) Diabetes Mellitus. Elsevier, New York, pp 357-377
39. Horton ES, Jeanrenaud B 1990 Obesity and diabetes mellitus. In: Rifkin H, Porte D (eds) Diabetes Mellitus. Elsevier, New York, pp 357-377
40. DeFronzo RA, Bonadonna RC, Ferrannini E 1992 Pathogenesis of NIDDM. Diabetes Care 15:318-368
41. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM 1996 IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271:665-668
42. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM 1994 Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 91:4854-4858
43. Hotamisligil GS, Shargill NS, Spiegelman BM 1993 Adipose tissue expression of tumor necrosis factor alpha: direct role in obesity-linked insulin resistance. Science 259:87-90
44. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM 1995 Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95:2409-2415
45. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM 1994 Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134:264-270